Clinical Insights Into Hypercalcemia of Malignancy in Childhood

Area of Science:

• Pediatric Oncology
• Pediatric Endocrinology
• Metabolic Emergencies

Background:

• Hypercalcemia of malignancy (HCM) is a rare, life-threatening condition in pediatric cancer patients, affecting <1% of cases.
• Unlike adults where solid tumors are the main cause, pediatric HCM is primarily associated with hematological malignancies like acute lymphoblastic leukemia (ALL).
• Monitoring calcium level trends offers insights into malignancy stage and prognosis; sudden, severe hypercalcemia indicates a poor outlook.

Purpose of the Study:

• To review the unique pathophysiology of HCM in children.
• To describe the clinical presentation of pediatric HCM.
• To discuss current therapeutic strategies for pediatric HCM.

Main Methods:

• This is a narrative review.
• Literature search on pediatric hypercalcemia of malignancy.
• Synthesis of information on pathophysiology, clinical features, and treatment.

Main Results:

• Pediatric HCM differs significantly from adult HCM in its common causes (hematological vs. solid tumors).
• Calcium level trends are crucial for assessing malignancy progression and patient prognosis.
• Acute, symptomatic hypercalcemia is a marker of poor prognosis.

Conclusions:

• Understanding the distinct features of pediatric HCM is vital for timely diagnosis and management.
• Current therapeutic strategies aim to address the underlying malignancy and manage calcium levels.
• Further research into specific pediatric HCM mechanisms and treatments is warranted.